Neha S Gandhi

Prof. Dr. Neha S Gandhi

School of Mathematical Sciences, Faculty of Science and Engineering, Queensland University of Technology, 2 George Street, Brisbane, QLD-4000, Australia
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2008 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
NGNeha S Gandhi
Neha S Gandhi
Ricardo L. ManceraRicardo L. Mancera
Ricardo L. Mancera

23 December 2020 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
CMCourtney J. Mycroft-West
Courtney J. Mycroft-West
DSDunhao Su
Dunhao Su
IPIsabel Pagani
Isabel Pagani
TRTimothy R. Rudd
Timothy R. Rudd
SEStefano Elli
Stefano Elli
MSMark SKIDMORE
Mark SKIDMORE
The dependence of development and homeostasis in animals on the interaction of hundreds of extracellular regulatory proteins with the peri- and extracellular glycosaminoglycan heparan sulfate (HS) is exploited by many microbial pathogens as a means of adherence and invasion. Heparin, a widely used anticoagulant drug, is structurally similar to HS and is a common experimental proxy. Exogenous heparin prevents infection by a range of viruses, including S-associated coronavirus isolate HSR1. Here, we show that heparin inhibits severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) invasion of Vero cells by up to 80% at doses achievable through prophylaxis and, particularly relevant, within the range deliverable by nebulisation. Surface plasmon resonance and circular dichroism spectroscopy demonstrate that heparin and enoxaparin, a low-molecular-weight heparin which is a clinical anticoagulant, bind and induce a conformational change in the spike (S1) protein receptor-binding domain (S1 RBD) of SARS-CoV-2. A library of heparin derivatives and size-defined fragments were used to probe the structural basis of this interaction. Binding to the RBD is more strongly dependent on the presence of 2-O or 6-O sulfate groups than on N-sulfation and a hexasaccharide is the minimum size required for secondary structural changes to be induced in the RBD. It is likely that inhibition of viral infection arises from an overlap between the binding sites of heparin/HS on S1 RBD and that of the angiotensin-converting enzyme 2. The results suggest a route for the rapid development of a first-line therapeutic by repurposing heparin and its derivatives as antiviral agents against SARS-CoV-2 and other members of the Coronaviridae. ∗ These authors are joint first authors. ∗∗ Senior authors. Received: 06 June 2020 Accepted: 13 October 2020 Publication Date: 23 December 2020 (online) © 2020. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

29 March 2022 in ACS Central Science
Verified
Journal Article
Open access
SGScott E. Guimond
Scott E. Guimond
CMCourtney J. Mycroft-West
Courtney J. Mycroft-West
NGNeha S Gandhi
Neha S Gandhi
JTJulia A. Tree
Julia A. Tree
TLThuy T. Le
Thuy T. Le
JTJeremy Turnbull
Jeremy Turnbull
Heparan sulfate (HS) is a cell surface polysaccharide recently identified as a coreceptor with the ACE2 protein for the S1 spike protein on SARS-CoV-2 virus, providing a tractable new therapeutic target. Clinically used heparins demonstrate an inhibitory activity but have an anticoagulant activity and are supply-limited, necessitating alternative solutions. Here, we show that synthetic HS mimetic pixatimod (PG545), a cancer drug candidate, binds and destabilizes the SARS-CoV-2 spike protein receptor binding domain and directly inhibits its binding to ACE2, consistent with molecular modeling identification of multiple molecular contacts and overlapping pixatimod and ACE2 binding sites. Assays with multiple clinical isolates of SARS-CoV-2 virus show that pixatimod potently inhibits the infection of monkey Vero E6 cells and physiologically relevant human bronchial epithelial cells at safe therapeutic concentrations. Pixatimod also retained broad potency against variants of concern (VOC) including B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and B.1.1.529 (Omicron). Furthermore, in a K18-hACE2 mouse model, pixatimod significantly reduced SARS-CoV-2 viral titers in the upper respiratory tract and virus-induced weight loss. This demonstration of potent anti-SARS-CoV-2 activity tolerant to emerging mutations establishes proof-of-concept for targeting the HS–Spike protein–ACE2 axis with synthetic HS mimetics and provides a strong rationale for clinical investigation of pixatimod as a potential multimodal therapeutic for COVID-19.

1 December 2010 in Drug Discovery Today
Verified
Journal Article
Closed access
NGNeha S Gandhi
Neha S Gandhi
Ricardo L. ManceraRicardo L. Mancera
Ricardo L. Mancera

1 October 2018 in Applied Surface Science
Verified
Journal Article
Closed access
PZping zhang
ping zhang
ADAijun Du
Aijun Du
NGNeha S Gandhi
Neha S Gandhi
YJYan Jiao
Yan Jiao
YZYaping Zhang
Yaping Zhang
Youhong TangYouhong Tang
Youhong Tang

1 December 2012 in Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
Verified
Journal Article
Closed access
NGNeha S Gandhi
Neha S Gandhi
Ricardo L. ManceraRicardo L. Mancera
Ricardo L. Mancera